Navigation Links
Isis Pharmaceuticals to Present a General Corporate Update at Its 2011 Annual Meeting of Stockholders and Open House
Date:5/23/2011

CARLSBAD, Calif., May 23, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a general corporate update in conjunction with its 2011 Annual Meeting of Stockholders and Open House on Thursday, June 16 at 2:15 p.m. Pacific Time in Carlsbad, CA.  The agenda for the meeting is as follows:2:00 p.m. – 2:15 p.m. Annual Meeting of Stockholders (only for stockholders of record as of April 20, 2011)2:15 p.m. – 3:00 p.m. Corporate Presentation – Stanley T. Crooke, Isis Chairman and Chief Executive Officer3:00 p.m. – 5:00 p.m. Poster PresentationA live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com.  A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.  The Company has successfully commercialized the world's first antisense drug and has 24 drugs in development.  Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer.  Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.  Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics.  Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing.  As an innovator in RNA-based drug discovery and development, Isis has designed and executed a patent strategy that has provided the Company with strong and extensive protection for Isis' drugs and technology.  Additional information about Isis is available at www.isispharm.com.


'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pacira Pharmaceuticals, Inc. Announces EXPARELâ„¢ Data Presentations at the International Anesthesia Research Society 2011 Annual Meeting
2. Onyx Pharmaceuticals Announces Updated Pivotal Carfilzomib Phase 2B Data
3. Johnson & Johnson to Host Pharmaceuticals Business Review
4. Unilife to Present at the 2011 UBS Global Specialty Pharmaceuticals Conference in London
5. Ampio Pharmaceuticals, Inc. to Begin Trading on the NASDAQ Capital Market
6. Cempra Pharmaceuticals to Present at Two Investor Conferences in Paris
7. Onyx Pharmaceuticals Announces Data Presentations of Carfilzomib and ONX 0912 at 47th American Society of Clinical Oncology Annual Meeting
8. Amylin Pharmaceuticals to Present at Annual Meeting of Stockholders
9. The Board of Directors of Kinex Pharmaceuticals Appoints Dr. David Hangauer as Chief Scientific Officer
10. Ampio Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Capital Market
11. Xanodyne Pharmaceuticals Appoints New Chief Operating Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Feb. 10, 2016  LexisNexis® Risk Solutions, a ... announced the launch of LexisNexis Provider Performance ... helps improve and optimize the quality and efficiency ... using severity-adjusted scores. By measuring provider performance through ... to deliver better outcomes, improve the patient experience ...
(Date:2/10/2016)... CORAL SPRINGS, Florida , February 10, 2016 ... Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS ) and Celldex Therapeutics, ... Medivation, Inc. (NASDAQ: MDVN ), Adamas Pharmaceuticals, Inc. (NASDAQ: ... ). --> Today,s latest Orphan Drug Designations become ... granted by the FDA to novel drugs and biologics which ...
(Date:2/10/2016)... , Feb. 10, 2016 /PRNewswire/ - The President ... has announced the release of an anti-radiation product ... a revolutionary breakthrough in the treatment of cancer ... exposure. It will assist in the healing of ... It will also protect only the healthy cells ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... Intermedix announced on Wednesday that ... an emergency medicine professional association, to support the organization's newly established physician group ... of Emergency Medicine, or AAEM, seeks to empower emergency physicians to control their ...
(Date:2/10/2016)... ... ... Emergency rooms provide emergency care to stabilize critical health issues, but emergency dental ... at risk of losing a tooth or their smiles. Dr. Marine Martirosyan, dentist ... include:, , Avulsed or knocked-out teeth , Dislodged ...
(Date:2/10/2016)... ... February 10, 2016 , ... Dr. Jessica Barron, of Barron Family Dental ... dental patients and families in the North Metro Denver area. The new dental practice ... cosmetic dentistry, and all in the most relaxing environment. , While some dental visits ...
(Date:2/10/2016)... IN (PRWEB) , ... February 10, 2016 , ... ... benefits advisory organization, welcomes S.S. Nesbitt as the latest addition to its growing ... has seven other locations throughout the Southeast, from Orlando to Huntsville and in ...
(Date:2/10/2016)... ... 10, 2016 , ... Armune BioScience signed a definitive agreement with ... service centers across the country. Launched in April of 2015, Apifiny is the only ... cancer. Apifiny order volume exceeded 3,000 tests in 2015. Primary care physicians and urologists ...
Breaking Medicine News(10 mins):